Compare Futu Holdings Ltd (FUTU) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs IDEXX Laboratories, Inc. — how do they compare? Futu Holdings Ltd trades at $105.5 (market cap $14.74B), while IDEXX Laboratories, Inc. trades at $570.81 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.1× Futu Holdings Ltd's market cap, and Futu Holdings Ltd pays a 2.47% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| FUTU | IDXX | |
|---|---|---|
Market Cap | $14.74B | $46.22B |
Sector | Financials | Health |
52-Week High | $199.04 | $766.68 |
52-Week Low | $89.76 | $526.44 |
Enterprise Value | $14.59B | $47.12B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings Limited (FUTU) trades at $108.70, showing modest daily movement with a slight decline of 0.29%. The stock exhibits a bullish technical trend, supported by moving averages, while recent earnings have been mixed with two misses and one beat against expectations. Strong revenue growth and profitability margins highlight solid fundamental performance, though the company faces significant legal and regulatory scrutiny.
The outlook for FUTU is cautiously optimistic, driven by robust financial health and analyst support, but overshadowed by ongoing securities class action lawsuits alleging regulatory compliance failures. Key risks include legal liabilities and market sentiment pressure, while opportunities lie in sustained earnings growth and favorable valuation metrics.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
